US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
09 juin 2020 06h00 HE
|
Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
Immuron Board Relinquish Cash Payment of Fees
28 avr. 2020 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
20 avr. 2020 06h00 HE
|
Immuron Limited
Key Highlights: North American sales up by 95% YoY in Q3 FY20Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20.YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57%...
Resignation of CEO & Director and cost cutting amidst COVID-19
25 mars 2020 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the...
Immuron Provides Update on First Half of FY20 Results
03 mars 2020 07h00 HE
|
Immuron Limited
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from first half FY 2019North...
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak
03 févr. 2020 07h30 HE
|
Immuron Limited
Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and gastrointestinal...
North American Travelan® sales up 98% in the first half of FY20
28 janv. 2020 08h30 HE
|
Immuron Limited
Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY growth for the first...
Immuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
08 janv. 2020 08h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
21 nov. 2019 07h00 HE
|
Immuron Limited
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to prevent TD planned for...
Immuron Receives AUD $0.53M R&D Tax Concession Refund
04 nov. 2019 11h30 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...